CAPLYTA improved bipolar mania by Day 3 in two Phase 3 trials. Can Johnson & Johnson unlock another blockbuster indication?
CAPLYTA met its second Phase 3 bipolar mania endpoint, strengthening Johnson & Johnson’s planned FDA filing for another major psychiatric indication.